European Commission reserves 200 million more coronavirus vaccines

The European Commission announced on Wednesday it has reached a deal with a sixth pharmaceutical firm, this time BioNTech-Pfizer, to reserve a further 200 million doses of a potential coronavirus vaccine. "Our chances to develop and deploy a safe and effective vaccine have never been higher, both for Europeans here at home, or for the rest of the world," European Commission president Ursula von der Leyen said. "To defeat coronavirus anywhere, we need to defeat it everywhere."

Brussels has previously signed deals with Sanofi-GSK, Johnson & Johnson, Curevac, Moderna and with AstraZeneca to be ready to procure doses quickly if and when any of the companies develop a safe and effective coronavirus vaccine. "We are optimistic that among these candidates there will be a safe and effective vaccine against Covid-19 to help us defeat this pandemic," the EU health commissioner, Stella Kyriakides, said.